Analysts Set Aptose Biosciences Inc. (NASDAQ:APTO) Price Target at $12.67
Aptose Biosciences Inc. (NASDAQ:APTO) has earned a consensus recommendation of “Buy” from the six analysts that are currently covering the firm. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $12.67.
Several equities research analysts have issued reports on APTO shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $23.00 price objective on shares of Aptose Biosciences in a research note on Saturday, June 25th. Zacks Investment Research downgraded shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 12th. Roth Capital upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $4.00 to $8.00 in a research note on Monday, June 13th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, June 9th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a research note on Thursday, June 9th.
Aptose Biosciences (NASDAQ:APTO) opened at 2.17 on Wednesday. Aptose Biosciences has a 12 month low of $1.92 and a 12 month high of $6.40. The firm’s 50-day moving average is $2.26 and its 200 day moving average is $2.54. The stock’s market capitalization is $27.98 million.
An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors own 19.43% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.